Generic substitution and therapeutic interchange, defined

In 2003 Kentucky became the first state to let a community pharmacist hand a patient a different drug from the one prescribed, as long as the prescriber had written "formulary compliance approval"¹ on the prescription and the new drug was in the same therapeutic class. Arkansas followed in 2015 and Idaho in July 2018, according to a 2018 review in the Journal of Managed Care & Specialty Pharmacy². As of that review, no other state had passed a comparable law.

Hospitals have done the same thing for more than 20 years. The same review found therapeutic interchange in use at more than 80 percent of hospitals since 2002, run through formularies that pharmacy and therapeutics committees write.

Both practices are easy to blur because both involve a pharmacist dispensing something other than the product named on the prescription. They rest on different legal footing. A generic substitution swaps one version of the same active ingredient for another, and state law lets pharmacists do it on their own. A therapeutic interchange swaps in a different molecule, and only a prescriber, directly or through an approved protocol, can authorize it. This explainer sets out the definitions, the federal and state rules behind each, and where the line sits in practice.

Generic substitution starts with the Orange Book

FDA's equivalence ratings cover only products with the same active ingredient. Generics "contain the same active ingredients" as the brand and have the same strength, dosage form and route of administration, FDA's generic drug Q&A says³. The agency rates such products therapeutically equivalent when they are also bioequivalent, and publishes the ratings as two-letter codes in the Orange Book; GxRadar's guide to therapeutic equivalence codes explains the letters.

FDA is explicit about the limit. The concept of therapeutic equivalence "applies only to drug products containing the identical active ingredient(s) and does not encompass a comparison of different therapeutic agents used for the same condition," the Orange Book preface⁴ says, giving meperidine hydrochloride versus morphine sulfate for pain as its example. Different salts of the same molecule fall outside it too, because FDA treats them as different active ingredients, a point covered in GxRadar's piece on salt forms and drug names.

Substitution itself is a matter of state law. Virtually every state has adopted laws or regulations that encourage it, the preface notes, and FDA built a single national list after states sought its help in the late 1970s. The rules still vary. A JAMA Internal Medicine study⁵ of laws as of Sept. 1, 2019, found that 19 states required pharmacists to substitute an available generic, while 31 states and Washington, DC, permitted but did not require it. Seven states and DC required the patient's consent. GxRadar's article on state generic substitution laws breaks those rules down.

Therapeutic interchange changes the molecule

ASHP, the professional society for health-system pharmacists, supplies the working definitions. Its guidelines on pharmacy and therapeutics committees and the formulary system⁶ define therapeutic alternatives as "drug products with different chemical structures but of the same pharmacologic or therapeutic class" that usually have similar effects and side-effect profiles in therapeutically equivalent doses. Therapeutic interchange is the "authorized exchange of therapeutic alternatives in accordance with previously established and approved written guidelines or protocols within a formulary system."

ASHP keeps a third term for the unauthorized version. In the ASHP glossary⁶, therapeutic substitution means dispensing a therapeutic alternative "without prior authorization of the prescriber," which the guidelines call illegal "because only the prescriber may authorize an exchange of therapeutic alternatives." Usage is not uniform: state laws and other writers use "therapeutic substitution" for authorized swaps as well, so the word alone does not settle which practice is meant.

The table draws on the Orange Book preface⁴, the 2021 JAMA Internal Medicine study⁵, the ASHP guidelines and the federal definition of an interchangeable biologic in 42 U.S.C. 262(i)(3)⁷.

How hospitals and drug plans build the authority

A hospital's interchange program runs on its formulary. Medicare's conditions of participation for hospitals require that "a formulary system must be established by the medical staff to assure quality pharmaceuticals at reasonable costs," under 42 CFR 482.25(b)(9)⁸. In ASHP's model, a pharmacy and therapeutics committee of physicians, pharmacists and other clinicians decides which drugs are on that list and which interchanges are approved, the guidelines say⁶.

Once a protocol exists, ASHP's guidelines say, therapeutic interchange gives pharmacists authority to use a formulary alternative in place of a nonformulary or nonpreferred drug "without having to contact the prescriber." The guidelines call for a process that lets a prescriber opt out and for notifying the clinicians and patients affected. They also say biosimilars are not generically equivalent to their reference products, so the committee should be involved in adding them, according to the same document⁶.

Medicare drug plans use committees too, for coverage decisions. Federal rules require a Part D plan's formulary to be developed by a pharmacy and therapeutic committee with a majority of practicing physicians or pharmacists, including at least one of each who is independent of the plan and of drug manufacturers, under 42 CFR 423.120(b)(1)⁹. The same section generally requires at least two drugs in each therapeutic category and class that are "not therapeutically equivalent and bioequivalent," so a plan cannot satisfy the rule with two interchangeable versions of the same product. GxRadar's explainers on tiered formularies and formulary exceptions cover how formularies shape coverage.

The three community-pharmacy laws

Outside hospitals, a pharmacist who wants to move a patient to a plan's preferred drug in the same class has generally had to call the prescriber and ask for a new prescription, the JMCP review² notes. The three states that changed that share a structure: the prescriber must opt in on the prescription, and the pharmacist must report back.

Those rows draw on the 2018 JMCP review² and, for Kentucky, the state's current rule. Kentucky's regulation, 201 KAR 2:280¹, last amended effective June 16, 2026, requires that the change come from the patient's third-party plan, that the preferred product be in the same therapeutic class, and that the pharmacist notify the prescriber in writing or by fax within 24 hours. Idaho alone explicitly excluded narrow therapeutic index drugs and biological products, the JMCP authors found. They also noted that therapeutic interchange could in principle occur in the 17 states that allowed population-specific collaborative practice agreements, though with practical obstacles.

Idaho's pharmacy board later recast its rules in a "standard of care" overhaul. A 2020 article by the board's former executive director in INNOVATIONS in pharmacy¹⁰ quotes the resulting rule as letting a pharmacist substitute a drug in the same therapeutic class if the patient opts in and the swap lowers the patient's cost or occurs during a drug shortage. The same article says a prescriber can still require that a prescription be dispensed as written.

For a patient, the practical distinction shows up on the label. A generic substitution leaves the active ingredient unchanged, while an interchange puts a different drug name on the bottle; GxRadar's guide to reading a prescription label shows where that name appears. Whether a change was a generic substitution, a plan-driven interchange or something else is a question for the pharmacist or prescriber who made it.